Staffan Widengren

In this interview, we at EPM magazine speak with Staffan Widengren, director of corporate projects at Recipharm on the difficulties CDMOs are facing leading up to the European Falsified Medicines Directive (EU FMD) deadline in February 2019. Read more


After a preview of TraceLink’s second annual Global Drug Supply, Safety and Traceability survey has revealed disparity in terms of readiness for the FMD between pharma companies and CMOs, three experts give us their perspectives on serialisation Read more

, , Opinion